NMN/NR (Nicotinamide Mononucleotide/Riboside) Cost in California 2026

How Much NMN and NR Actually Cost in California

The price you pay depends on whether you choose compounded NMN (prescription required) or over-the-counter NR. Compounded nicotinamide mononucleotide from a California-licensed 503A pharmacy runs about $80 per month for a standard 250 to 500 mg daily dose. Nicotinamide riboside, sold as Tru Niagen or similar brands, costs $40 to $60 monthly at retail.

These two molecules serve the same basic purpose: raising intracellular NAD+ levels. NAD+ declines roughly 50% between ages 40 and 60, according to a 2018 review in Cell Metabolism [1]. Both NMN and NR act as precursors that cells convert into NAD+ through slightly different enzymatic pathways.

Price variation across California is real. A compounding pharmacy in Los Angeles may charge $65 for the same formulation that costs $95 in San Francisco due to differences in overhead and sourcing. Online 503A pharmacies licensed in California sometimes offer lower prices because they operate with reduced storefront costs. OTC nicotinamide riboside pricing is more uniform, with major retailers like Costco, CVS, and Amazon clustering between $42 and $58 for a 30-day supply of 300 mg capsules [2].

One factor worth tracking: sublingual NMN formulations typically cost 15 to 25% more than oral capsules. The sublingual route bypasses first-pass liver metabolism, which some clinicians argue improves bioavailability, though head-to-head pharmacokinetic data comparing sublingual versus oral NMN in humans remains limited.

Why NMN and NR Are Priced Differently

NMN requires a prescription for the compounded form because the FDA excluded it from the dietary supplement category in October 2022. NR did not receive the same exclusion. This regulatory split explains the pricing gap.

The FDA's decision rested on the fact that NMN was under active investigation as a new drug (IND) before it was marketed as a supplement [3]. That investigation, led by Metro International Biotech, meant NMN could no longer be sold over the counter under the Federal Food, Drug, and Cosmetic Act's drug exclusion provision. NR, by contrast, had established supplement market presence before any IND was filed, so it retained its supplement status.

For Californians, this means NR is the cheaper, more accessible option. You can buy it at any pharmacy or health food store. NMN, by contrast, requires a clinician's prescription and must be sourced from a compounding pharmacy operating under FDA Section 503A or 503B rules. The California Board of Pharmacy oversees these facilities and conducts regular inspections to verify potency, sterility (for injectable forms), and labeling accuracy [4].

"The distinction between NMN and NR from a clinical standpoint is modest. Both raise NAD+ levels effectively in human studies," noted Dr. Charles Brenner, the biochemist who discovered NR's role as a vitamin precursor to NAD+ [5]. "The regulatory difference is what drives the cost difference, not the pharmacology."

California Medi-Cal Coverage for NMN/NR

Medi-Cal can cover compounded NMN with prior authorization, but approval is not guaranteed. The prescribing clinician must document medical necessity, and the request typically goes through Medi-Cal's Rx prior authorization process.

In practice, Medi-Cal approvals for NAD+ precursors remain uncommon. The program generally reserves prior authorization approvals for conditions with strong evidence-based treatment protocols. NAD+ precursor therapy, while supported by emerging clinical data, does not yet appear in major U.S. treatment guidelines for any specific condition. Yoshino et al. demonstrated in a 2021 randomized controlled trial (N=25) that NMN at 250 mg daily for 10 weeks improved skeletal muscle insulin sensitivity in prediabetic postmenopausal women, but the trial was small and the FDA has not approved NMN for any indication [6].

If Medi-Cal denies your prior authorization, you have the right to appeal. California's Department of Health Care Services allows beneficiaries to request a fair hearing within 90 days of denial. Your prescriber can also submit a peer-to-peer review with the Medi-Cal medical director.

NR supplements do not require Medi-Cal coverage because they are sold without a prescription at retail prices. Medi-Cal does not cover OTC supplements unless they appear on the program's covered OTC list, and NR is not currently listed.

Private Insurance and NMN/NR in California

Most California health plans, including those from Kaiser Permanente, Blue Shield of California, Anthem Blue Cross, and Health Net, do not include NMN or NR on their formularies. These products fall outside standard drug coverage because NMN has no FDA-approved indication and NR is classified as a supplement.

Some exceptions exist. A small number of employer-sponsored plans with lifestyle medicine or longevity benefits have begun covering compounded NAD+ precursors as part of wellness packages. These plans are rare and concentrated among tech companies in the Bay Area and Los Angeles that offer expanded health spending accounts (HSAs) or lifestyle spending accounts (LSAs).

If your plan includes an HSA or flexible spending account (FSA), compounded NMN prescribed by a licensed clinician may qualify as an eligible medical expense. The IRS allows HSA/FSA reimbursement for prescribed medications, including compounded drugs [7]. OTC NR supplements generally do not qualify for HSA/FSA reimbursement unless your plan has a letter of medical necessity on file.

Covered California marketplace plans follow the state's Essential Health Benefits benchmark, which does not include NAD+ precursor therapy. Out-of-network compounding pharmacy charges will not count toward your plan's out-of-pocket maximum.

Compounded NMN Through California 503A Pharmacies

California permits compounding pharmacies licensed under Section 503A to prepare NMN formulations with a valid patient-specific prescription. The California Board of Pharmacy maintains oversight through inspections, adverse event reporting requirements, and compliance with USP compounding standards (USP <795> for non-sterile and USP <797> for sterile preparations) [4].

To obtain compounded NMN in California, you need three things. First, a prescription from a licensed prescriber (MD, DO, NP, or PA). Second, a 503A pharmacy licensed by the California Board of Pharmacy. Third, documentation that the compounded product is for an individual patient, not for bulk distribution.

Pricing at California 503A pharmacies typically breaks down like this:

• NMN 250 mg oral capsules, 30-count: $50 to $75
• NMN 500 mg oral capsules, 30-count: $75 to $110
• NMN sublingual tablets, 250 mg, 30-count: $70 to $95
• NMN with added TMG (trimethylglycine), 30-count: $85 to $120

Several California-based compounding pharmacies offer subscription pricing that reduces per-month cost by 10 to 20% for patients who commit to 3-month or 6-month supplies. Auto-refill programs through mail-order 503A pharmacies can drop the effective monthly cost of 250 mg NMN capsules to approximately $55 to $65.

Quality verification matters. Ask your compounding pharmacy for a certificate of analysis (COA) showing third-party purity testing. Reputable pharmacies test each batch for NMN content, heavy metals, and microbial contamination.

Telehealth Access to NMN/NR in California

California law permits telehealth prescribing of compounded NMN. The Medical Board of California and the California Business and Professions Code Section 2290.5 authorize clinicians to prescribe via audio-video telehealth visits, provided the clinician conducts an appropriate examination and documents the clinical rationale [8].

Telehealth platforms specializing in longevity medicine have expanded rapidly in California. A typical telehealth consultation for NAD+ precursor therapy costs $75 to $200 for an initial visit, with follow-up visits at $50 to $100. Some platforms bundle the consultation fee with a 90-day NMN prescription and compounding pharmacy fulfillment for $200 to $350 total.

The telehealth workflow is straightforward. You complete a health questionnaire. A licensed California clinician reviews your history, conducts a video consultation, and (if appropriate) writes a prescription for compounded NMN. The prescription is sent electronically to a 503A pharmacy, which ships the product to your California address.

One consideration: California requires that the prescribing clinician hold an active California medical license or practice under a valid interstate compact agreement. Out-of-state telehealth providers without California licensure cannot legally prescribe compounded NMN to California residents.

Clinical Evidence for NMN and NR

The evidence base for NAD+ precursors in humans is growing but still early-stage. Several randomized controlled trials have been published, though none with the sample sizes typical of Phase III drug trials.

Yoshino et al. published the first placebo-controlled trial of NMN in humans in Science (2021). The study enrolled 25 postmenopausal women with prediabetes and randomized them to NMN 250 mg daily or placebo for 10 weeks. NMN increased skeletal muscle insulin signaling by 25% and improved muscle glucose uptake, though it did not significantly change fasting glucose, HbA1c, or body weight [6]. The result was mechanistically interesting but clinically preliminary.

For NR, the data set is larger. Martens et al. (2018) conducted a crossover trial in 24 lean, healthy adults aged 55 to 79 and found that NR 1,000 mg daily for 6 weeks raised whole-blood NAD+ levels by 60% compared to placebo [9]. Systolic blood pressure decreased by a mean of 5.4 mmHg in participants with Stage 1 hypertension, though this was a secondary endpoint in a small subgroup.

Dollerup et al. (2018) tested NR 2,000 mg daily for 12 weeks in 40 obese, insulin-resistant men. NAD+ metabolites increased significantly, but insulin sensitivity, resting energy expenditure, and body composition did not change [10].

"We are in the phase of establishing proof-of-concept in humans. The mouse data are remarkable, but translation to clinical endpoints in humans requires larger, longer trials," said Dr. Shin-ichiro Imai, a professor at Washington University School of Medicine who has studied NAD+ biology for over two decades [11].

A 2020 systematic review in Translational Medicine of Aging identified 11 completed human trials of NR or NMN, with sample sizes ranging from 8 to 140 participants and durations of 2 to 16 weeks [12]. None reported serious adverse events, and NAD+ increases were consistent across studies.

How to Reduce Your NMN/NR Costs in California

Several strategies can lower what you pay. Start with NR if you do not need a compounded formulation. At $40 to $60 per month OTC, NR is the most cost-effective way to raise NAD+ levels. The clinical data for NR and NMN show comparable NAD+ elevation at standard doses [9].

If you need compounded NMN, compare at least three California 503A pharmacies before filling your prescription. Price differences of 30 to 40% for the same formulation and dose are common. Ask about subscription pricing, multi-month discounts, and auto-refill programs.

Consider dose optimization. Some clinicians start patients at 250 mg daily and only increase to 500 mg if NAD+ blood levels (measured via whole-blood NAD+ assays) remain below target ranges. Starting at the lower dose cuts your monthly cost nearly in half.

Use an HSA or FSA if your employer offers one. Compounded NMN with a valid prescription qualifies as an eligible expense under IRS guidelines. Keep your prescription and pharmacy receipts for documentation.

Manufacturer savings cards exist for some branded NR products. Tru Niagen, for example, offers a subscription discount of approximately 20% through its direct-to-consumer website. ChromaDex (Tru Niagen's manufacturer) also periodically runs promotions that bring 90-day supply costs below $100.

Finally, ask your prescriber about combination approaches. Some longevity clinicians prescribe lower-dose NMN (250 mg) alongside trimethylglycine (TMG) to support methylation, which may produce equivalent NAD+ outcomes at a lower NMN dose and cost.

Safety and Monitoring Considerations

NAD+ precursors have a favorable safety profile in published human trials. No serious adverse events attributable to NMN or NR have been reported across the 11 completed trials identified in systematic review [12]. Common side effects are mild and include flushing, mild nausea, and transient GI discomfort.

Monitoring recommendations vary by clinician. Many longevity medicine practitioners check baseline whole-blood NAD+ levels before starting therapy and repeat the test at 8 to 12 weeks to confirm a meaningful increase. This test costs $100 to $250 out of pocket at most California labs, as insurance rarely covers it.

Patients on anticoagulants, diabetes medications, or cancer therapy should discuss NAD+ precursor use with their prescribing oncologist or primary care physician. Preclinical data suggest that NAD+ elevation could theoretically promote tumor growth in certain cancer models, though this has not been demonstrated in human studies [13]. The Endocrine Society has not issued formal guidelines on NAD+ precursor therapy, and prescribing remains at clinician discretion.

Liver function tests (ALT, AST) at baseline and at 3 months represent a reasonable monitoring approach, given that high-dose NR (2,000 mg daily) produced modest ALT elevations in one trial, though values remained within normal limits [10].